JNNP-phosphorylated tau and neurofilament light chain protein can complement each other's strengths and predict cognitive ability

Alzheimer’s disease (AD) is characterized by misfolded amyloid β (Aβ) and phosphorylated tau (p-tau) proteins, which are found in senile plaques outside the cell and neurofibrillary tangles inside neurons, respectively.
The brain piles up
.

A clear diagnosis of AD requires confirmation of these pathological features at autopsy, but due to the development of reliable cerebrospinal fluid (CSF) and PET measurements of Aβ and tau burden, it has been possible to accurately determine the diagnosis of AD in vivo
.

As the clinical use of AD-modifying drugs that reduce Aβ accumulation has recently become a reality, a widely applicable and accurate risk-adaptive, personalized prevention and treatment method has become imperative
.

However, many aspects of blood-based measurement methods still need to be further studied, including longitudinal trajectories measured in the same human body and their relationship with cognitive decline and changes in PET tau load
.

The main purpose is to explore the changes of p-tau181 and NfL measured in plasma in the NIA-AA biomarker group over time, and to explore the relationship between the baseline peptide concentration and time trajectory and memory performance, tau and PET Aβ accumulation after 6 years How
.

They used 865 ADNI cohort participants, used the established AD cut-off point of Aβ42, total tau and p-tau181, classified the subjects according to NIA-AA, and divided the markers into Aβ deposition (A) and tau pathology ( T) and neurodegeneration (N)
.

The important significance of this study is that it is found that the performance of P-tau and NfL in the same person is different over time, so it may provide complementary diagnostic information
.